Complete Resolution of Hypercortisolism with Sorafenib in a Patient with Advanced Medullary Thyroid Carcinoma and Ectopic ACTH (Adrenocorticotropic Hormone) Syndrome

Barroso‐Sousa, Romualdo; Lerário, Antônio Marcondes; Evangelista, J. J. F.; Papadia, Carla; Lourenço, Delmar M.; Lin, Chin Shien; Kulcsar, Marco Aurélio Vamondes; Fragoso, Maria Candida Barisson Villares; Hoff, Ana O.

doi:10.1089/thy.2013.0571

Cited by 32 publications

(22 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In three reports, the tyrosine kinase inhibitors vandetanib and sorafenib rapidly and fully controlled hypercortisolism caused by ACTH secretion from metastatic medullary thyroid carcinomas (162)(163)(164). The dissociation between the decrease in ACTH secretion and the lack of tumor reduction suggests a direct antisecretory effect.…”

Section: Targeted Therapies For Ectopic Acth Syndromementioning

confidence: 99%

Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline

Nieman

Biller

Findling

et al. 2015

The Journal of Clinical Endocrinology & Metabolism

1,016

959

View full text Add to dashboard Cite

Treatment of Cushing's syndrome is essential to reduce mortality and associated comorbidities. Effective treatment includes the normalization of cortisol levels or action. It also includes the normalization of comorbidities via directly treating the cause of Cushing's syndrome and by adjunctive treatments (eg, antihypertensives). Surgical resection of the causal lesion(s) is generally the first-line approach. The choice of second-line treatments, including medication, bilateral adrenalectomy, and radiation therapy (for corticotrope tumors), must be individualized to each patient.

show abstract

Section: Targeted Therapies For Ectopic Acth Syndromementioning

confidence: 99%

Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline

Nieman

Biller

Findling

et al. 2015

The Journal of Clinical Endocrinology & Metabolism

1,016

959

View full text Add to dashboard Cite

show abstract

“…Until recently, the management of this challenging situation, associated to extreme morbidity and mortality, was limited to surgical removal of metastatic disease, medical therapy with anti-adrenal compounds or bilateral adrenalectomy. Nevertheless, recent reports indicate successful treatment of MTC-related Cushing syndrome with TKIs ( Barroso-Sousa et al 2014, Nella et al 2014.…”

Section: :9mentioning

confidence: 99%

Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives

Ceolin

Duval

Benini

et al. 2019

Endocrine-Related Cancer

109

View full text Add to dashboard Cite

Medullary thyroid carcinoma (MTC) is a rare type of tumor that originates from thyroid C cells and accounts for 2–4% of all malignant thyroid neoplasms. MTC may occur sporadically or be inherited, as part of the MEN 2 syndrome. Germline mutations of the RET (REarranged during Transfection) proto-oncogene cause hereditary cancer, whereas somatic RET mutations and, less frequently, RAS mutations have been described in sporadic MTC samples. Since early surgery with complete resection of tumor mostly determines the likelihood of attaining cure for MTC, the broader use of RET genetic screening has dramatically changed the prognostic of gene carriers in hereditary MTC. Nevertheless, despite recent advances, the management of advanced, progressive MTC remains challenging. The multikinase inhibitors (MKI), vandetanib and cabozantinib, were approved for the treatment of progressive or symptomatic MTC, and several other compounds have exhibited variable efficacy. Although these drugs have been shown to improve progression-free survival, no MKI has been shown to increase the overall survival. As these drugs are nonselective, significant off-target toxicities may occur, limiting achievement of the required TK-specific inhibition. Recently, next-generation small-molecule TKI has been developed. These TKI are specifically designed for highly potent and selective targeting of oncogenic RET alterations, making them promising drugs for the treatment of advanced MTC. Here, we summarize the current understanding of the intracellular signaling pathways involved in MTC pathogenesis as well as the therapeutic approaches and challenges for the management of advanced MTC, focusing on targeted molecular therapies.

show abstract

“…Recently, four cases of ECS associated to MTC with rapid response to tyrosine kinase inhibitors have been published: to sunitinib (16), sorafenib (17) and vandetanib treatments (18,19) (Table 1).…”

Section: Discussionmentioning

confidence: 99%

Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome

Pitoia

Bueno

Schmidt

et al. 2015

Arch. Endocrinol. Metab.

View full text Add to dashboard Cite

Complete Resolution of Hypercortisolism with Sorafenib in a Patient with Advanced Medullary Thyroid Carcinoma and Ectopic ACTH (Adrenocorticotropic Hormone) Syndrome

Cited by 32 publications

References 18 publications

Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline

Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline

Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives

Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome

Contact Info

Product

Resources

About